Freshfields represented Novartis in its acquisition of DTx Pharma, a biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications. The transaction involved an upfront payment of $500 million and additional payments upon completion of pre-specified milestones.

The Freshfields team is led by Adam Golden and Jenny Hochenberg and included Counsel Vinita Sithapathy and Associates Sora Park, Daria Butler and Joshua Samuel on Corporate and Life Sciences matters.